Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
Farnesoid-X receptor (FXR), as a nuclear receptor activated by bile acids, is a vital molecule involved in bile acid metabolism. Due to its expression in immune cells, FXR has a significant effect on the function of immune cells and the release of chemokines when immune cells sense changes in bile a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1016836/full |
| _version_ | 1828162577879793664 |
|---|---|
| author | Mengjiao Zhou Danfeng Wang Xiang Li Ying Cao Chengxue Yi Dickson Kofi Wiredu Ocansey Dickson Kofi Wiredu Ocansey Yuling Zhou Fei Mao |
| author_facet | Mengjiao Zhou Danfeng Wang Xiang Li Ying Cao Chengxue Yi Dickson Kofi Wiredu Ocansey Dickson Kofi Wiredu Ocansey Yuling Zhou Fei Mao |
| author_sort | Mengjiao Zhou |
| collection | DOAJ |
| description | Farnesoid-X receptor (FXR), as a nuclear receptor activated by bile acids, is a vital molecule involved in bile acid metabolism. Due to its expression in immune cells, FXR has a significant effect on the function of immune cells and the release of chemokines when immune cells sense changes in bile acids. In addition to its regulation by ligands, FXR is also controlled by post-translational modification (PTM) activities such as acetylation, SUMOylation, and methylation. Due to the high expression of FXR in the liver and intestine, it significantly influences intestinal homeostasis under the action of enterohepatic circulation. Thus, FXR protects the intestinal barrier, resists bacterial infection, reduces oxidative stress, inhibits inflammatory reactions, and also acts as a tumor suppressor to impair the multiplication and invasion of tumor cells. These potentials provide new perspectives on the treatment of intestinal conditions, including inflammatory bowel disease (IBD) and its associated colorectal cancer (CRC). Moreover, FXR agonists on the market have certain organizational heterogeneity and may be used in combination with other drugs to achieve a greater therapeutic effect. This review summarizes current data on the role of FXR in bile acid metabolism, regulation of immune cells, and effects of the PTM of FXR. The functions of FXR in intestinal homeostasis and potential application in the treatment of IBD and CRC are discussed. |
| first_indexed | 2024-04-12T00:57:15Z |
| format | Article |
| id | doaj.art-b49fb30a87a7438a85a89cca5f1bcf33 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T00:57:15Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-b49fb30a87a7438a85a89cca5f1bcf332022-12-22T03:54:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10168361016836Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancerMengjiao Zhou0Danfeng Wang1Xiang Li2Ying Cao3Chengxue Yi4Dickson Kofi Wiredu Ocansey5Dickson Kofi Wiredu Ocansey6Yuling Zhou7Fei Mao8Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, ChinaNanjing Jiangning Hospital, Nanjing, Jiangsu, ChinaKey Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, ChinaKey Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, ChinaSchool of Medical Technology, Zhenjiang College, Zhenjiang, Jiangsu, ChinaKey Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, ChinaDirectorate of University Health Services, University of Cape Coast, Cape Coast, GhanaNanjing Jiangning Hospital, Nanjing, Jiangsu, ChinaKey Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, ChinaFarnesoid-X receptor (FXR), as a nuclear receptor activated by bile acids, is a vital molecule involved in bile acid metabolism. Due to its expression in immune cells, FXR has a significant effect on the function of immune cells and the release of chemokines when immune cells sense changes in bile acids. In addition to its regulation by ligands, FXR is also controlled by post-translational modification (PTM) activities such as acetylation, SUMOylation, and methylation. Due to the high expression of FXR in the liver and intestine, it significantly influences intestinal homeostasis under the action of enterohepatic circulation. Thus, FXR protects the intestinal barrier, resists bacterial infection, reduces oxidative stress, inhibits inflammatory reactions, and also acts as a tumor suppressor to impair the multiplication and invasion of tumor cells. These potentials provide new perspectives on the treatment of intestinal conditions, including inflammatory bowel disease (IBD) and its associated colorectal cancer (CRC). Moreover, FXR agonists on the market have certain organizational heterogeneity and may be used in combination with other drugs to achieve a greater therapeutic effect. This review summarizes current data on the role of FXR in bile acid metabolism, regulation of immune cells, and effects of the PTM of FXR. The functions of FXR in intestinal homeostasis and potential application in the treatment of IBD and CRC are discussed.https://www.frontiersin.org/articles/10.3389/fphar.2022.1016836/fullFarnesoid X Receptorimmune cellspost-translational modificationinflammatory bowel diseasecolorectal cancertherapy |
| spellingShingle | Mengjiao Zhou Danfeng Wang Xiang Li Ying Cao Chengxue Yi Dickson Kofi Wiredu Ocansey Dickson Kofi Wiredu Ocansey Yuling Zhou Fei Mao Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer Frontiers in Pharmacology Farnesoid X Receptor immune cells post-translational modification inflammatory bowel disease colorectal cancer therapy |
| title | Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| title_full | Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| title_fullStr | Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| title_full_unstemmed | Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| title_short | Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| title_sort | farnesoid x receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer |
| topic | Farnesoid X Receptor immune cells post-translational modification inflammatory bowel disease colorectal cancer therapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1016836/full |
| work_keys_str_mv | AT mengjiaozhou farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT danfengwang farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT xiangli farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT yingcao farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT chengxueyi farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT dicksonkofiwireduocansey farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT dicksonkofiwireduocansey farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT yulingzhou farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer AT feimao farnesoidxreceptorasatherapeutictargetforinflammatoryboweldiseaseandcolorectalcancer |